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Anthony S. Stein,1 Joycelynne M. Palmer,2 Margaret R. O’Donnell,1 Neil M. Kogut,3
Ricardo T. Spielberger,3 Marilyn L. Slovak,2 Ni-Chun Tsai,2 David Senitzer,2 David S. Snyder,1
Sandra H. Thomas,1 Stephen J. Forman1Acute lymphoblastic leukemia (ALL) with high-risk features has a poor prognosis in adults despite aggressive
chemotherapy. Reduced-intensity conditioning (RIC) is a lower toxicity alternative for high-risk patients
requiring hematopoietic cell transplantation (HCT); however, it has not been widely used for ALL. We con-
ducted a retrospective study of 24 high-risk adult ALL patients who received an RIC regimen of fludarabine
(Flu)/melphalan (Mel) prior to allogeneic peripheral blood stem cell transplantation (PBSCT) between 6/14/02
and 6/15/07 at the City of Hope. Indications for the RIC regimen were: (1) aged 50 years or older
(42%), (2) compromised organ function (54%), or (3) recipient of a previous HCT (37.5%). Patients
had a median age of 47.5 years and the median follow-up was 28.5 months for living patients. Both
overall survival (OS) and disease-free survival (DFS) at 2 years was 61.5%. Relapse incidence was
21.1% and nonrelapse mortality (NRM) was 21.5% at 2 years. Chronic graft-versus-host (cGVHD) de-
veloped in 86% of evaluable patients. In this series, no significant correlations were made between out-
comes and patient age, presence of Philadelphia chromosome, relatedness of donor source, or prior
HCT. These high survival rates for high-risk ALL patients following RIC HCT may offer a promising
option for patients not eligible for a standard myeloablative transplant.
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Acute lymphoblastic leukemia (ALL) has a poor
prognosis in adult patients, with a 5-year overall sur-
vival (OS) rate of 39% to 50% despite aggressive che-
motherapy [1-3], and only 15% for patients over 50
years of age [3]. In patients with high-risk disease, as
determined by age, cytogenetics, remission status,
and/or response to induction therapy, survival out-
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6/j.bbmt.2009.07.003MRC/ECOG ALL Trial of chemotherapy versus au-
tologous and allogeneic transplant, allogeneic hemato-
poietic cell transplantation (HCT) confers the greatest
durable benefit for standard-risk adult patients and is
more effective than either chemotherapy or autolo-
gous transplant [4]. Goldstone et al. [4] also show,
however, that for patients over 45 years and others
with high-risk ALL, a high nonrelapse mortality
(NRM) of 36% offsets any potential survival advantage
of the reduced relapse rate conferred by myeloablative
(MA) transplant. Patients requiring transplants who
are over the age of 50 years, have impaired organ func-
tion, or have had previous ablative therapy are unable
to withstand the toxicity of the MA protocols that
are standard of care.
In the last 10 years, the goal of reducing treatment-
related mortality (TRM) has led to the investigation of
a variety of reduced-intensity, nonmyeloablative con-
ditioning (RIC, NMA) protocols for allogeneic HCT
in patients with multiple hematologic malignancies
[5-8]. In a study comparing RIC to standard HCT,
NRM (22% versus 30%) and OS (59% versus 52%)
were comparable [8]. Similar to observations in the
MAtransplant setting,Mohty et al. [7] describe a strong1407
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(cGVHD) with a reduction in relapse incidence from
55% to 30%, suggesting a primary role for graft-ver-
sus-leukemia (GVL) in the achievement of remission
via RIC HCT.
Four small (22-33 patients) prospective studies
[9-12] and a larger (97 patients) retrospective study
[13] have attempted to assess the feasibility and effec-
tiveness of RIC specifically for treatment of ALL in
high-risk populations. The 2-year OS rates for these
studies average 32% (median: 31%, range: 18%-50%),
with variable, but high, relapse rates andTRM, depend-
ing upon remission status. Consensus conclusions from
these studies appear to be that improved survival is asso-
ciated with RIC transplant during first complete remis-
sion (CR1) and that relapse incidence (RI) is lower for
patients exhibiting GVHD.
In most published studies of RIC in ALL [9-
11,13], multiple sources of hematopoietic stem cells
(HSCs) and pretransplant conditioning regimens
were included in the same data set, making it difficult
to obtain the best and most consistent results. In this
study, we have removed the issue of transplantation
regimen variation; all patients were treated at the
City of Hope with peripheral blood stem cell trans-
plantation (PBSCT) following the same RIC regimen.
Based on this more homogeneous treatment and stem
cell source, we report a high survival rate among high-
risk ALL patients receiving RIC.PATIENTS AND METHODS
Inclusion Criteria
A retrospective analysis was conducted on 24 high-
risk ALL patients treated between 6/14/02 and 6/15/
07 with a uniform RIC SCT protocol at the City of
Hope. The indications for the RIC regimen were 1
or more of the following: (1) patient aged 50 years or
older (42%), (2) compromised organ function (54%),
or (3) recipient of a previous HCT (37.5%). Indica-
tions for HCT during CR1 included age over 35,
high white blood cell (WBC) count (.50,000) at diag-
nosis, multiple rounds of induction chemotherapy
required to achieve remission, and/or poor prognosis
cytogenetics (e.g., Philadelphia chromosome or
t[4;11][q21;q23]). Cytogenetic risk level, based on
Pullarkat et al. [14], is indicated in Table 1 as Level
2, 3, 4 or Philadelphia chromosome positive (Ph1)
(in increasing order of severity). The City of Hope in-
stitutional review board approved the retrospective
study and analysis of this patient case series.Patients
Salient patient characteristics for all 24 patients
are displayed in Table 1. Fifteen women and 9 menwere part of the study, with a median age of 47.5
years (range: 23-68 years). Seven patients (29%) had
a previous allogeneic HCT and 2 (8%) had a previous
autologous HCT. In addition to the high-risk factors
for which they were included in this study, the patient
population exhibited additional risk factors that could
affect outcome: 67% of the PBSC donors were unre-
lated to the recipients, 54% of patients were beyond
CR1 at the time of transplant, and 42% were Ph1.
Three patients had ALL that was secondary to a prior
malignancy: patient #1 had prior multiple myeloma
(MM), #4 breast cancer, and #10 had both a history
of chronic lymphocytic leukemia (CLL) and germ
cell cancer. One patient, #9, also had a coexisting
myelodysplastic syndrome (MDS) at the time of
transplant.
Listed first in Table 1 are the 10 patients in CR1
(42%), followed by 1 CR1 patient (#11) who was not
inmolecular remission (4%), 4 patients in second com-
plete remission (CR2, 17%), 1 induction failure (4%),
3 in first relapse (R1, 12%), 1 in second relapse (R2,
4%), and 4 in third CR or beyond ($CR3, 17%).
For patients in CR1, the median time between remis-
sion and transplant was 2.3 months (range: 0.5-5.7),
40% required 2 courses of chemotherapy to achieve
remission and the median WBC at diagnosis was
21.5 (range: 0.6-70). Patients not in remission at the
time of transplant had a median WBC prior to condi-
tioning of 3.3 (range: 0.9-7.8), a median of 1% blasts in
the bone marrow (BM) (range: 0-15), and a median of
0% blasts in the blood (range: 0-21).
Matched sibling donors were available for 8 of the
24 (33%) patients in the study. For the 16 patients
lacking suitable related donors, HLA matched unre-
lated donors (MUDs) were successfully identified
through the National Marrow Donor Program
(NMDP). HLA typing was performed using polymer-
ase chain reaction (PCR) sequence-specific primers
(SSP) or PCR sequence-specific oligonucleotide probe
(SSOP) techniques. Of the MUD transplants, mis-
matches were as follows: 10 patients were matched at
10 of 10 loci, 3 patients had 2 antigen mismatches, 1
patient was allele mismatched, and 1 patient had 2
allele mismatches and an antigen mismatch.Treatment Regimen
TheRIC regimen for all patients consisted of i.v. Flu
at 25 mg/m2 daily for 5 days followed by i.v. melphalan
(Mel) at 140 mg/m2 for 1 day. Subsequently, patients re-
ceived allogeneicPBSCmobilizedwith granulocyte col-
ony stimulating factor (G-CSF). Eight of the 10 Ph1
patients were treated with thymidine kinase inhibitors
(TKI) pre- and/orpost-transplant.Table 2 showsdetails
of treatment for Ph1 patients, including type and dura-
tion of TKI therapy.
Table 1. RIC Patient Data
Pt No. Sex Age at RIC
Compromised
Organ Systems PriorHCT Status at RIC
Donor
Type GVHD Prophylaxis
Cytogenetic Risk
Level*
aGVHD
Grade
cGVHD
Grade
Outcome dd5 death on day
rd5 relapse on day Survivor KPS (%)
1 F 45 none Yes CR1 MUD TAC/SIR/MTX Level 2 Grade III Extensive infection: dd 195 NA
2 F 62 none No CR1 MUD CsA/MMF/MTX Ph+ None Extensive alive in remission 90%
3 F 57 none No CR1 MUD CsA/MMF/MTX Ph+ Grade III None infection: dd 245 NA
4 F 57 none No CR1 SIB CsA/MMF Ph+ Grade II Extensive relapsed, rd 857alive after second RIC 90%
5 F 56 renal No CR1 SIB TAC/SIR Ph+ None Limited alive in remission 80%
6 M 61 cardiac No CR1 MUD CsA/MMF/MTX Ph+ Grade II Limited alive in remission 90%
7 F 62 cardiac, lung No CR1 SIB TAC/SIR Unknown Grade II Limited alive in remission 80%
8 F 54 renal, cardiac No CR1 MUD TAC/SIR/MTX Level 3 Grade II Limited alive in remission 90%
9 F 46 renal, cardiac No CR1 MUD TAC/SIR/MTX Level 2 Grade II NA multiple organ failure: dd 34 NA
10 M 49 prior chemo/radiation No CR1 MUD TAC/SIR Level 3 Grade I Limited alive in remission 100%
11 M 38 none Yes CR1† MUD CsA/MMF/MTX Ph+ Grade IV NA idiopathic interstitial
pneumonitis: dd 29
NA
12 M 28 spine irradiation No CR2 MUD CsA/MMF/MTX Unknown Grade I Extensive alive in remission Unknown
13 F 68 none Yes CR2 MUD ATG/CsA/MMF Ph+ Grade II None disease progression: rd 532,
dd 570
NA
14 F 31 none Yes CR2 SIB TAC/SIR Unknown None Extensive disease progression: rd 96, dd 283 NA
15 F 41 lung No CR2 MUD TAC/SIR/MTX Level 2 Grade III Extensive disease progression: rd 207, dd 209 NA
16 F 50 none Yes CR2 MUD CsA/MMF/MTX Level 2 Grade II Extensive alive in remission 90%
17 F 54 pneumonia No Induction
Failure
SIB TAC/SIR Ph+ Grade I Extensive alive in remission 80%
18 M 32 none Yes R1 MUD CsA/MMF/MTX Ph+ None Extensive alive in remission 90%
19 F 43 cirrhosis of liver Yes R1 SIB CsA/MMF Level 2 Grade II Extensive alive in remission 100%
20 F 48 none Yes R1 MUD CsA/MMF/MTX Ph+ Grade II Extensive disease progression: rd 156 ,dd 162 NA
21 M 42 none Yes R2 MUD TAC/SIR/MTX Level 2 None None alive in remission 90%
22 M 47 pneumonia,
leukoencephalopathy
No $CR3 SIB TAC/SIR Level 2 Grade III NA leukoencephalopathy dd 53 NA
23 M 23 cardiac,
leukoencephalopathy
No $CR3 SIB TAC/SIR Unknown None Extensive alive in remission 90%
24 M 27 cardiac, lung No $CR3 MUD TAC/SIR/MTX Level 2 Grade II Extensive alive in remission 90%
KPS indicates Karnofsky Performance Status score (defined in [18]); CR, complete remission; MUD, matched unrelated donor; TAC, tacrolimus; SIR, sirolimus; MTX, methotrexate; NA, not applicable; CsA, cyclo-
sporine; MMF, mycophenylate mofetil; Ph+, Philadelphia chromosome positive; SIB, sibling donor; ATG, antithymocyte globulin; R, remission; RIC, reduced-intensity conditioning; aGVHD, acute graft-versus-host
disease; cGVHD, chronic graft-versus-host disease.
*Cytogenetic risk Level defined [14].
†Not in molecular remission.
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Table 2. Ph+ Patient Data
Pt No.
Status
at RIC
TKI
(pre-HCT) TKI (post-HCT) Outcome
2 CR1 none none alive in remission
3 CR1 imatinib none dead, infection
4 CR1 imatinib dasatinib, 4 years relapsed, second RIC
5 CR1 imatinib imatinib, 2.5 years alive in remission
6 CR1 imatinib imatinib, 3 years alive in remission
11 CR1, mol+ none none dead, IP
13 CR2 imatinib dasatinib, 1 year dead, progression
17 Ind failure imatinib dasatinib, 2 months alive in remission
18 R1 imatinib imatinib, 5 years alive in remission
20 R1 imatinib imatinib, 2.5 months dead, progression
TKI indicates thymidine kinase inhibitor; HCT, hematopoietic cell trans-
plantation; CR, complete remission; mol+, molecular positive; Ind, in-
duction; IP, interstitial pneumonitis; RIC, reduced-intensity conditioning.
1410 Biol Blood Marrow Transplant 15:1407-1414, 2009A. S. Stein et al.The GVHD prophylactic treatment regimen and
the maximal extent of acute (aGVHD) and cGVHD
manifestations are listed in Table 1 for each patient.
Prophylactic treatment of GVHD varied between pa-
tients depending on theirHLAmatch and the available
protocols at the time of transplant and included: cyclo-
sporine (CsA) plus mycophenylate mofetil (MMF) in 2
patients, CsA/MMF plus methotrexate (MTX) in 8 pa-
tients, CsA/MMF plus antithymocyte globulin (ATG)
in 1 patient, tacrolimus plus sirolimus in 7 patients,
and tacrolimus/sirolimus plus MTX in 6 patients.
No patient in this study group was treated using donor
leukocyte infusion (DLI).Statistics
Survival estimates were calculated based on the
product-limit method, and 95% confidence intervals
were calculated using the logit transformation and
the Greenwood variance estimate [15]. Differences be-
tween survival curves were assessed by the log rank
test. The significance of demographic/treatment fea-
tures collected from HCT recipients was assessed us-
ing survival analysis and univariate Cox regression
analysis [16]. The list of features included was deter-
mined from a literature review that identified factors
found to be associated with survival and disease relapse
in patients treated with allogeneic RIC HCT. Statisti-
cal significance was defined at the value of P #.05.RESULTS
Engraftment
All 24 patients engrafted successfully. The median
time, postengraftment, to reach an absolute neutrophil
count (ANC) of$500, was 15 days (range: 10-26 days),
and a platelet count $20,000 was 16.5 days (range:
8-24 days). At day 30 postengraftment, short tandem
repeat (STR) analysis of BM showed a median of
100% donor cells (range: 90%-100%).GVHD
Eighteen patients (75%) developed aGVHD,
which was graded according to consensus criteria
[17]. Three patients displayed grade I aGVHD, 15
had grade II-IV, with 5 of those suffering grade III
or IV. Of the 21 patients evaluable 100 days posten-
graftment, 18 developed cGVHD (86%); 13 were clas-
sified with extensive disease, and 5 with limited
cGVHD. Three patients did not develop any symp-
toms of cGVHD. The 3 patients not evaluable for
cGVHD died prior to 100 days postengraftment. We
also noted that 9 of the patients had cGVHD with
acute features: 4 cases developed progressively from
aGVHD, 3 were acute/chronic overlap syndromes,
and 2 cases were delayed acute onset (after day100).
Only 1 patient exhibited neither aGVHD (grade II
or above) nor cGVHD (4%).Outcomes
Relapse and death events are reported as days post-
HCT and cause of death is listed in Table 1 in the out-
come column. Fifteen of the 24 patients were living
and disease-free at analysis date, 1 of whom had re-
lapsed (patient #4), but was disease-free 1 year after
a second RIC transplant. Karnofsky Performance Sta-
tus (KPS) scores [18] for survivors are listed in the last
column, with all patients at 80% or above and able to
carry on relatively normal activity. The KPS score
for 1 surviving patient was unobtainable. Of the 13 sur-
viving patients with cGVHD, at the date of analysis, 6
patients had active disease and remained on immuno-
suppressive therapy, 5 patients had inactive disease
and were tapering medications (3 tacrolimus only),
and 3 patients were completely off cGVHD medica-
tions. Duration of TKI therapy for Ph1 patients is
shown in Table 2. TKI therapy was discontinued be-
cause of side effects, relapse, or with cessation of im-
munosuppressive therapy.
Median follow-up for living patients was 28.5
months (range: 12.8-72.5 months). OS and disease-
free survival (DFS) at 2 years were both 61.5%, with
a confidence interval (CI) of 48.1% to 72.5%. Survival
curves for OS and DFS are displayed in Figure 1A and
B, respectively. Figure 1B also shows the RI curve,
with RI at 14.6% (CI of 5.8%-33.9%) at 1 year and
21.1% (CI of 10.2%-40.7%) at 2 years. NRM was
12.5% (CI of 4.8%-30.2%) at day 100, 21.5% (CI of
11.4%-38.3%) at 1 year and at 2 years, and is charted
in Figure 1A. For NRM causes of death in individual
patients, see Table 1.
The log rank test was applied to these data to de-
termine whether there were any significant correla-
tions between OS, DFS, RI, or NRM and known
variables in the patient population. In contrast to other
studies in the literature, at the date of analysis there
were no significant relationships found. In particular,
AB
Figure 1. RIC outcomes. Median follow-up was 28.5 months (A) OS
and NRM, (B) DFS and RI.
A
B
Figure 2. CR1 versus .CR1 outcomes. Median follow-up for the 10
CR1 patients was 22.7 months and for the 14 patients at .CR1 was
16.4 months (A) OS and (B) RI.
Biol Blood Marrow Transplant 15:1407-1414, 2009 1411Reduced-Intensity PBSCT for ALLpresence of Ph1 did not affect outcome (60% alive at
time of analysis, see Table 2), nor did patient age
$47 (75% living). Use of an unrelated donor and prior
HCT also were not significant factors for outcome
with 56% of MUD recipients and 44% of prior
HCT recipients alive at the time of analysis. Compar-
ison of patients in CR1 versus those beyond CR1 also
yielded no significant differences with respect to out-
come and the OS and RI curves are shown in Figure 2.
Although some studies have shown a correlation be-
tween outcome and the occurrence of cGVHD, no
meaningful tests could be performed comparing
groups with and without symptoms of cGVHD, as
the overwhelming majority of patients exhibited
some level of GVHD. Of the 18 patients with
cGVHD, 9 had some acute features, either progressive
development, overlap syndrome, or delayed acute on-
set. There was no significant difference in outcomes
for the 9 patients with acute features compared to
the rest of the population.DISCUSSION
ALL is relatively rare in adults and its incidence in-
creases dramatically with age. The cumulative inci-
dence of ALL cases (per 100,000 of age-matched
population) triples in the .50 age group compared to
the25-49 age group [19]. Additionally, theolder patient
population has a higher incidence of Ph1, exemplified
by the Southwest Oncology Group (SWOG) study in
which the median age is 32 years for the total study
group and 47 years for Ph1 patients [14].Older patients
havea verypoorprognosiswithoutHCT,but aregener-
ally ineligible forMAtransplants because of highNRM,
as demonstrated in the MRC/ECOG ALL Trial [4].
Goldstone et al. [4] conclude, based on their results in
older patients, that research on RIC transplant regi-
mens in ALL is imperative to reduce morbidity and of-
fer a viable alternative to high-risk patients. RIChas the
potential to extend the benefit of transplant to those
1412 Biol Blood Marrow Transplant 15:1407-1414, 2009A. S. Stein et al.older patients for whom standard chemotherapy is not
effective long term.
Based on the limited ability ofDLI to produce aCR
in relapsed ALL (only 18% as opposed to 60% for
chronic myelogenous leukemia [CML]) [20], some be-
lieve that a GVL effect is not clinically important in
ALL. Rowe and Goldstone [21] have suggested that
the lack of response to DLI may be related to the fact
that the DLI study involved patients in active relapse,
whereas transplant patients are generally in remission,
allowing for a more effective allogeneic response to tu-
mor cells. Several transplant studies do, in fact, suggest
that there is a therapeutic GVL effect in ALL, based on
a correlation betweenGVHD and a decrease in relapse
incidence among ALL patients, following both MA
[22,23] and RIC [7,11] allogeneic HCT. The disparity
between DLI-associated and transplant-associated
GVL effects may also be because of differences in the
ability of ALL blasts to present target antigens, the fre-
quency ofminor-antigen reactiveT cell precursors, cell
cycle kinetics, or susceptibility to lysis [24].
The development of RIC for ALLwould give high-
risk patients transplant options and hope for disease
control with fewer complications. Several studies have
attempted to assess the efficacy of RIC for treatment
of high-riskALL; however,mostwere small and the pa-
tient populations and treatment regimens were hetero-
geneous. In this study at the City of Hope, all patients
received a Flu/Mel conditioning regimen and the
stem cell source was PBSC. Despite the poor prognos-
tic indicators and limited sample size, the 2-year OS
and DFS of 61.5% for this patient population are en-
couraging. In comparison, the recent MRC/ECOG
ALL Trial shows that standard risk ALL patients re-
ceiving allogeneic transplants have a 5-year OS of
62%, whereas the Philadelphia chromosome negative
(Ph2) high-risk trial patients have an OS of 41% and
Ph1 patient OS is only 22% [4].
The 21.5% NRM at 2 years compares very favor-
ably with the International ALL Trial 2-year NRM
of 35.8% for high-risk myeloablative transplant pa-
tients. The 2-year relapse rate of 21.1% was also sim-
ilar to the 2-year rate of 25% from the International
ALL Trial (interpolated from a 10-year graph) [4].
At 100 days NRM was 12.5%; however, an increase
to 21.5% by 2 years posttransplant was attributable
to cGVHD and associated infections.
Nearly all patients hadGVHDto someextent (23of
24 patients), and PBSCT is known to correlate with
higher risk of GVHD [25]. The incidence of cGVHD
was a cause of concern; however, in surviving patients,
KPS scores were 80% to 100%, allowing a reasonably
functional life after transplant. Jagasia finds that pa-
tients having cGVHD with any acute features have
a poorer prognosis. In this group, half of the cGVHD
cases had some acute features, only 2 of which were de-
layed acute presentation. There was no correlationbetween cGVHD with acute features and poor out-
come.The lowrelapse rates in this studymaybepartially
attributable to high GVHD; however, direct statistical
tests were inconclusive because of patients numbers.
This study is consistent with the recent findings of
Bachanova et al. [12] using CB for ALL RIC, whose
22-patient study is of similar size, high-risk patient
composition and outcome. Both studies have a rela-
tively low incidence of relapse (Stein and Forman
[24] 2 years: 21%, Bachanova et al. [12] 3 years:
36%), especially for first remission patients after the
second year. Although the stem cell sources and treat-
ment details differ, both studies show significant im-
provement in OS compared to previously published
data (Stein and Forman [24] 2 years: 61%, Bachanova
et al. [12] 3 year: 50%).
Analysis of this data from 24 high-risk ALL pa-
tients did not find a significant association between
age and survival; however, that is not unexpected given
the skewed age distribution and sample size. Although
younger patients might be expected to demonstrate
significantly better outcomes in a larger, more age-
diverse study, we demonstrate highly acceptable sur-
vival rates for older patients receiving RIC. Patients
too old to be candidates for MA therapies may now
be considered reasonable candidates for RIC PBSCT
transplants. In this study, unrelated donor transplant
patients had survival rates comparable to patients
with related donors. A similar finding for unrelated do-
nors is also recently reported for elderly patients in
a large acute myelogenous leukemia (AML) transplant
study (368 patients) [26] and in the recent CB ALL
study [12]. For older patients, MUD transplant surviv-
ability is an important consideration, as the availability
of eligible sibling donors diminishes with patient age.
Despite the high-risk nature of the patients in this
study, all had low disease burden at the time of trans-
plant, either in a complete remission or with low
WBC and % blasts. Forty-two percent of patients
were in CR1; however, no significant difference in out-
come was detected for these patients compared to
those beyond CR1. We are aware that this result is
in contrast to the published literature and attribute
this to the small sample size.
For adult Ph1 ALL patients, a safer alternative to
standard allo-HCT is especially important. Histori-
cally, this population had a dismal survival rate of
10% to 20%when treatedwith standard chemotherapy
alone [1,14,27]. Use of imatinib mesylate and other ty-
rosine-kinase inhibitors is improving remission rates
and durable responses, allowing for improved trans-
plant [28] and nontransplant [29] survival. Despite
this fact, allo-HCT is considered the only curative
approach, and is the standard of care in CR1 for Ph1
ALL patients [27,28,30]. Even though the presence of
the Philadelphia chromosomewas not part of the selec-
tion criteria for RIC in this study, 42% of patients were
Biol Blood Marrow Transplant 15:1407-1414, 2009 1413Reduced-Intensity PBSCT for ALLPh1, reflecting the increased incidence of Philadelphia
chromosome in older patients. Of the 10 Ph1 patients
in this study, 5 have survived in remission, a DFS of
50% that is comparable to the DFS of Ph1 patients
seen in a collaborative study by this group and Stanford
(Ph1 DFS in CR15 48%, beyond CR15 26%) [31].
Because of increasing prevalence of Ph1 with increas-
ing age [28,32], the availability of effective reduced-in-
tensity transplants is a crucial addition to the treatment
armamentarium for these patients.
In conclusion, this retrospective study demon-
strates optimistic survival rates for patients with
high-risk ALL undergoing RIC, comparable to those
seen in the literature for standard-risk patients under-
going myeloablative allo-HCT. These data also con-
tribute to the body of evidence supporting a role for
GVL in the treatment of ALL. Studies describing
RIC transplant for ALL are scarce in the literature,
and there are as yet no single-protocol prospective tri-
als. Although our findings are exciting, the caveats of
the retrospective nature of the study and its small sam-
ple size can be addressed only through future prospec-
tive trials in adults with ALL. To validate these
findings and those of other studies, we plan to use
this preliminary data as the basis of a proposal for
a large phase II prospective clinical trial of reduced-
intensity transplant in patients with high-risk ALL.ACKNOWLEDGMENTS
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